Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model
Liang Zhang, Xiaoping Zhang, Glen W. Barrisford, Aria F. OlumiVolume:
251
Year:
2007
Language:
english
Pages:
158
DOI:
10.1016/j.canlet.2006.11.013
File:
PDF, 2.14 MB
english, 2007